Melinta Therapeutics (NASDAQ:MLNT) posted its earnings results on Tuesday. The biotechnology company reported ($1.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.89), Morningstar.com reports. Melinta Therapeutics had a negative return on equity of 45.72% and a negative net margin of 500.05%.
Shares of Melinta Therapeutics (NASDAQ:MLNT) opened at $12.20 on Wednesday. Melinta Therapeutics has a twelve month low of $10.25 and a twelve month high of $24.25. The company has a current ratio of 11.49, a quick ratio of 11.49 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $382.17, a price-to-earnings ratio of -1.66 and a beta of 1.08.
In other Melinta Therapeutics news, Director Vatera Healthcare Partners Llc acquired 5,777,778 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $78,000,003.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 31.50% of the company’s stock.
A number of analysts have weighed in on the company. Zacks Investment Research lowered Melinta Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. BidaskClub lowered Melinta Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. ValuEngine lowered Melinta Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Gabelli upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Finally, Ladenburg Thalmann Financial Services upgraded Melinta Therapeutics from a “neutral” rating to a “buy” rating in a report on Thursday, November 30th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.56.
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.